ABEO

ABEO

USD

Abeona Therapeutics Inc. Common Stock

$6.245+0.045 (0.726%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$6.200

Максимум

$6.310

Минимум

$6.100

Объем

0.72M

Фундаментальные показатели компании

Рыночная капитализация

319.5M

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

1.67M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $3.93Текущая $6.245Максимум $7.32

Связанные новости

Analyst Upgrades

Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19

Oppenheimer analyst Andreas Argyrides assumes Abeona Therapeutics with a Outperform rating and announces Price Target of $19.

Просмотреть больше
Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19
GlobeNewswire

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in

Просмотреть больше
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analyst Upgrades

Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20

Stifel analyst Dae Gon Ha maintains Abeona Therapeutics with a Buy and lowers the price target from $21 to $20.

Просмотреть больше
Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20
GlobeNewswire

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric

Просмотреть больше
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of

Просмотреть больше
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.